RalA-binding Protein 1 is an Important Regulator of Tumor Angiogenesis
RalA-binding Protein 1 is an Important Regulator of Tumor Angiogenesis
Journal of Life Science. 2014. May, 24(5): 588-593
Copyright © 2014, Korean Society of Life Science
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Received : March 04, 2014
  • Accepted : May 09, 2014
  • Published : May 30, 2014
Export by style
Cited by
About the Authors
승형, 이

Tumor angiogenesis is important in tumorigenesis and therapeutic interventions in cancer. To know inhibitor and effector of tumor angiogenesis in cancer, the specific gene of tumor and angiogenesis may develop the mechanisms of cancer suppression and therapy. Recently, we described the role of RalA-binding protein 1 (RLIP76) in tumor angiogenesis. Tumor vascular volumes were diminished, and vessels were fewer in number, shorter, and narrower in RLIP76 knockout mice than in wild-type mice. Moreover, angiogenesis in basement membrane matrix plugs was blunted in the knockout mice in the absence of tumor cells, with endothelial cells isolated from the lungs of these animals exhibiting defects in migration, proliferation, and cord formation in vitro . RLIP76 is expressed in most human tissues and is overexpressed in many tumor types. In addition, the protein regulates tumorigenesis and angiogenesis in vivo and in vitro . As the export of chemotherapy agents is a prominent cellular function of RLIP76, it is a major factor in mechanisms of drug resistance. Moreover, RLIP76 acts as a selective effector of the small GTPase, R-Ras, and regulates R-Ras signaling, leading to cell spreading and migration. Furthermore, in skin carcinogenesis, RLIP76 knockout mice are resistant, with tumors that form showing diminished angiogenesis. Thus, RLIP76 is required for efficient endothelial cell function and angiogenesis in solid tumors.
RalA-binding protein 1 (RLIP76) plays an important role in cancer, such as melanoma regression, regression of lung and colon cancer, colorectal cancer, breast cancer, and carcinoma cancer [ 21 , 24 , 32 , 35 , 36 ]. RLIP76 knockout mice are highly resistant to chemical carcinogenesis and are even resistant to the growth of subcutaneously implanted cancer cells [ 20 , 21 , 32 , 33 , 36 , 37 , 41 ]. Recently, we have been published in RLIP76 regulates tumor angiogenesis in vivo and in vitro , these studies suggest that suppression of RLIP76 can inhibit vascular growth and/or angiogenesis for tumor angiogenesis.
Tumor angiogenesis is important for tumor growth and therapeutic intervention in cancer. These primarily consist of the release of angiogenic factors, activation of metalloproteases to break down extracellular matrix, and subsequent remodeling. Also angiogenic stimulants induced in tumor cells and produced, and endothelial cells are responded in proliferation, migration, spreading, and angiogenesis to tumor. To know inhibitor and/or its effector of tumor angiogenesis in cancer, the specific gene of tumor and angiogenesis may develop the mechanisms of cancer suppression and therapy. This review will focus on the function and role of RLIP76 in tumor angiogenesis and cancer.
- Functions of RLIP76
RLIP76 is a modular, multifunctional protein of 655 amino acids, harboring an N-terminal putative helical domain of poorly characterized function, a central RhoGAP domain, and a conserved Ral-binding domain (RalBD) near the C-terminus ( Fig. 1 ). Like all Ras superfamily small G proteins, Ral proteins are signal transducers that become activated upon release of guanine diphosphate (GDP) and binding to guanine triphosphate (GTP), upon which Ral undergoes a conformational shift to expose high affinity binding sites for signaling effectors. Thus RLIP76 is a unique Ral effector, connecting upstream activation of Ral to downstream molecular and cellular events.
Also the Ral effector property of RLIP76 was described as linking Ral to Rho GTPase pathways through the RhoGAP domain [ 9 , 17 , 44 ]. The Rho subfamily of Ras small G proteins, most prominently RhoA, Rac and Cdc42, are, like Ras and Ral, regulated by guanine nucleotide exchange, such that RhoGAPs facilitate conversion from the GTPbound, active state to the GDP-bound, inactive state. Thus, an important cellular and physiological function of RLIP76 is to couple Ral effector function with Rho signaling and actin cytoskeletal remodeling, promoting altered cell morphologies.
PPT Slide
Lager Image
Schematic diagram of the RLIP76.
Moreover, our group identified RLIP76 as a selective effector of the small GTPase R-Ras, and found that RLIP76 regulates R-Ras signaling leading to cell spreading and migration [ 8 , 11 ]. These effects are the result of RLIP76 adapter function, whereby it recruits ARNO, a small GTPase guanine exchange factor, to R-Ras at recycling endosomes to regulate vesicular trafficking necessary for spreading and migration [ 8 ]. RLIP76 also potentiates Ral-mediated cell spreading, potentially through similar signaling pathways [ 7 ]. Thus, RLIP76 regulates a broad spectrum of molecular, cellular and physiological processes, many of which stem from its function as a molecular adapter in various cellular locales ( Fig. 2 ).
- RLIP76 in cancer
RLIP76 is expressed in most human tissues including liver, heart, ovary, lung, muscle, and kidney as well as in most human tumor cell lines, and is over-expressed in multiple cancers, such as lung and ovarian carcinomas and melanomas [ 3 , 4 , 6 , 28 ]. Since a prominent cellular function of RLIP76 is export of chemotherapy agents, it is a major factor in the mechanisms of drug resistance. Moreover, blockade of RLIP76 with targeting antibodies or antisense has been shown to greatly increase sensitivity to radiation and chemotherapy and lead to pronounced tumor regression in multiple types of solid tumors in mice, including xenografted tumors of cancer cells [ 32 , 33 , 36 ].
PPT Slide
Lager Image
Summary of RLIP76 functions in cells.
Of the many functions of RLIP76 related to cancer initiation and progression, the most thoroughly characterized is as a molecular transporter of glutathione-electrophile conjugates (GS-E). GS-Es form by thioether conjugation of glutathione (GSH, between 1–10 mM cytolosic concentration in cells), an electron donor and thus a reducing agent, with electrophilic or oxidant chemicals that are derived both endogenously (endobiotics) and from the environment (xenobiotics). In this way, GSH acts as a scavenger for alkylating agents and other electrophiles [ 15 ]. GS-E conjugates become trapped in cells, and require energy-dependent transport for their removal to prevent toxicity both by excessive GS-E and by impairing the overall process of reduction of electrophilic toxins [ 16 , 42 ]. Some of this transport function is carried out by ATP-binding cassette (ABC) transporters [ 1 , 10 ]. Thus, in addition to removal from cells of toxic endobiotics such as 4-hydroxynonenal (4-HNE), GS-E transport is also essential for protection from xenobiotics [ 16 , 43 ]. Multi-drug resistance (MDR), particularly for alkylating chemotherapeutic drugs, is very often the result of a failure of transport in the target cells; hence, transporters such as ABC type are classified as MDR proteins, which have long been pursued as therapeutic targets to inhibit drug resistance in cancer cells [ 19 , 29 ].
RLIP76 is a novel, non-ABC type transporter, which utilizes both of its two ATP binding sites - in the N-terminal domain (aa 69-74) and adjacent to the RalBD (418-425) - for ATPase and transport activity, but lacks the canonical Walker domain of ABC-type transporters [ 25 ]. Interestingly, PKC-mediated phosphorylation of RLIP76 increases its transport activity [ 27 ]. A wealth of subsequent studies showed that RLIP76 is the major transporter for a wide range of structurally distinct endobiotics and xenobiotic chemotherapy agents, including GS-E, doxorubicin, sulfates, leukotriene C4, vinorelbine, glucorinides, colchicine, and other organic anions and cations [ 2 , 5 , 27 , 30 , 34 , 36 , 38 , 39 ]. Due to this broad spectrum of transport targets, RLIP76 plays important roles in resistance to apoptosis due to heat shock and oxidative stress (in part through interaction with HSF-1), radiation sensitivity, and perhaps most prominently, to multi-drug resistance in cancer therapy [ 22 , 37 , 40 ].
- RLIP76 regulates tumor angiogenesis
RLIP76 has unique functions in endothelial cells, specialized squamous epithelia that form the inner core of all blood vessels, and are the sole cellular components of the microvasculature [ 14 , 21 ]. We have recently found a role for RLIP76 in tumor angiogenesis ( Fig. 3 ). Angiogenesis, the outgrowth of new blood vessels from existing ones, is required for progression of tumor growth and metastasis. Solid tumors require a nutrient blood supply to grow beyond ~1 mm diameter, and inhibiting tumor angiogenesis has long been pursued as an approach to preventing tumor growth and subsequent metastasis [ 23 ]. Angiogenesis is a complex process resulting from combined simultaneous up-regulation of proliferation and migration in endothelial cells. During initial stages of angiogenesis, proliferating and migrating endothelial cells convert to a spindle-shaped morphology and organize into branched capillary networks, which differentiate into fully-formed lumenal vessels carrying blood from the source vasculature to the new sites such as into solid tumors [ 23 ].
PPT Slide
Lager Image
Quantification of tumor vasculature in wild type and RLIP76 knock-out mice. B16F10 melanoma and LLC carcinoma tumor cells were cultured, and injected into flank of wild type and RLIP76 knock-out mice. Collected solid tumors scanned by micro-CT, and analyzed total volume (A), micro-vascular density (B), specific surface area (C), and vessel tortuosity (D) using micro-CT software program and analyze 10.0.
Based on the ability of RLIP76 to interact with R-Ras – a modulator of tumor angiogenesis – as well as with other proteins important for endothelial function, we recently investigated a potential physiological role for RLIP76 in angiogenesis in solid tumors xenografted in mice [ 18 ]. Tumor growth from B16F10 melanoma or Lewis lung carcinoma cells xenografted into the flanks of C57Bl/6 wild type (WT) mice was blunted in isogenic RLIP76 -/- mice. We used X-ray micro-computed tomography to reconstruct tumor vascular structures in 3D in resected tumors from WT and RLIP76 knock-out mice, and found defects in both the extent and form of tumor angiogenesis in RLIP76 knock-out mice. Specifically, tumor vascular volumes were diminished and vessels were fewer in number, shorter, and narrower in RLIP76 knock-out mice than in WT mice. Moreover, we found that angiogenesis in basement membrane matrix plugs was blunted in the knockout mice in the absence of tumor cells, with endothelial cells isolated from the lungs of these animals exhibiting defects in migration, proliferation and cord formation in vitro [ 14 ]. Furthermore, in a model of induced skin carcinogenesis, to which RLIP76 knock-out mice are already resistant [ 13 ], the tumors that did form showed diminished angiogenesis; conversely, liposomemediated reconstitution of RLIP76 expression restored tumor growth and tumor angiogenesis in this model [ 14 ]. Thus, in addition to regulating tumor cell growth, RLIP76 is required for efficient endothelial cell function and angiogenesis in solid tumors.
In tumor angiogenesis, effects of RLIP76 targeting in tumor xenografts are the result of combinatorial effects in tumor cells and stromal cells. The prevention of xenografted tumor growth and synergy with inhibition of tumor angiogenesis in RLIP76 knockout mice, and conversely the enhanced tumor angiogenesis observed following ectopic application of RLIP76 in the knockout mice, strongly supports the idea of a one-two punch attack on growth of solid tumors, by blocking RLIP76 function in tumor cells and the tumor vasculature.
This work was supported by American Heart Association Grant 12POST12040257 to S.L.
Ambudkar S. V. , Dey S. , Hrycyna C. A. , Ramachandra M. , Pastan I. , Gottesman M. M. 1999 Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 361 - 398    DOI : 10.1146/annurev.pharmtox.39.1.361
Awasthi S. , Sharma R. , Singhal S. S. , Zimniak P. , Awasthi Y. C. 2002 RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics Drug Metab Dispos 30 1300 - 1310    DOI : 10.1124/dmd.30.12.1300
Awasthi S. , Singhal S. S. , Awasthi Y. C. , Martin B. , Woo J. H. , Cunningham C. C. , Frankel A. E. 2008 RLIP76 and Cancer Clin Cancer Res 14 4372 - 4377    DOI : 10.1158/1078-0432.CCR-08-0145
Awasthi S. , Singhal S. S. , Srivastava S. K. , Zimniak P. , Bajpai K. K. , Saxena M. , Sharma R. , Ziller S. A. , Frenkel E. P. , Singh S. V. 1994 Adenosine triphosphate-dependent transport of doxorubicin, daunomycin, and vinblastine in human tissues by a mechanism distinct from the P-glycoprotein J Clin Invest 939 58 - 965
Awasthi S. , Singhal S. S. , Yadav S. , Singhal J. , Drake K. , Nadkar A. , Zajac E. , Wickramarachchi D. , Rowe N. , Yacoub A. , Boor P. , Dwivedi S. , Dent P. , Jarman W. E. , John B. , Awasthi Y. C. 2005 RLIP76 is a major determinant of radiation sensitivity Cancer Res 65 6022 - 6028    DOI : 10.1158/0008-5472.CAN-05-0968
Awasthi Y. C. , Singhal S. S. , Gupta S. , Ahmad H. , Zimniak P. , Radominska A. , Lester R. , Sharma R. 1991 Purification and characterization of an ATPase from human liver which catalyzes ATP hydrolysis in the presence of the conjugates of bilirubin bile acids and glutathione Biochem Biophys Res Commun 175 1090 - 1096    DOI : 10.1016/0006-291X(91)91677-5
Awasthi Y. C. , Ansari G. A. , Awasthi S. 2005 Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferases Methods Enzymol 401 379 - 407    DOI : 10.1016/S0076-6879(05)01024-4
Awasthi Y. C. , Chaudhary P. , Vatsyayan R. , Sharma A. , Awasthi S. , Sharma R. 2009 Physiological and pharmacological significance of glutathione-conjugate transport J Toxicol Environ Health B Crit Rev 12 540 - 551    DOI : 10.1080/10937400903358975
Bauer B. , Mirey G. , Vetter I. R. , Garcia-Ranea J. A. , Valencia A. , Wittinghofer A. , Camonis J. H. , Cool R. H. 1999 Effector recognition by the small GTP-binding proteins Ras and Ral J Biol Chem 274 17763 - 17770    DOI : 10.1074/jbc.274.25.17763
Borst P. , Evers R. , Kool M. , Wijnholds J. 2000 A family of drug transporters: the multidrug resistance-associated proteins J Natl Cancer Inst 92 1295 - 1302    DOI : 10.1093/jnci/92.16.1295
Cheng J. Z. , Sharma R. , Yang Y. , Singhal S. S. , Sharma A. , Saini M. K. , Singh S. V. , Zimniak P. , Awasthi S. , Awasthi Y. C. 2001 Accelerated metabolism and exclusion of 4-hydroxynonenal through induction of RLIP76 and hGST5.8 is an early adaptive response of cells to heat and oxidative stress J Biol Chem 276 41213 - 41223    DOI : 10.1074/jbc.M106838200
Downey C. M. , Singla A. K. , Villemaire M. L. , Buie H. R. , Boyd S. K. , Jirik F. R. 2012 Quantitative ex-vivo micro-computed tomographic imaging of blood vessels and necrotic regions within tumors PLoS One 7 e41685 -
Goldfinger L. E. , Ptak C. , Jeffery E. D. , Shabanowitz J. , Han J. , Haling J. R. , Sherman N. E. , Fox J. W. , Hunt D. F. , Ginsberg M. H. 2007 An experimentally derived database of candidate Ras-interacting proteins J Proteome Res 6 1806 - 1811    DOI : 10.1021/pr060630l
Heitzer T. , Schlinzig T. , Krohn K. , Meinertz T. , Munzel T. 2001 Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease Circulation 104 2673 - 2678    DOI : 10.1161/hc4601.099485
Ishikawa T. 1992 The ATP-dependent glutathione S-conjugate export pump Trends Biochem Sci 17 463 - 468    DOI : 10.1016/0968-0004(92)90489-V
Jedlitschky G. , Leier I. , Buchholz U. , Barnouin K. , Kurz G. , Keppler D. 1996 Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump Cancer Res 56 988 - 994
Jullien-Flores V. , Dorseuil O. , Romero F. , Letourneur F. , Saragosti S. , Berger R. , Tavitian A. , Gacon G. , Camonis J. H. 1995 Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity J Biol Chem 270 22473 - 22477    DOI : 10.1074/jbc.270.38.22473
Komatsu M. , Ruoslahti E. 2005 R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis Nat Med 11 1346 - 1350    DOI : 10.1038/nm1324
LaBelle E. F. , Singh S. V. , Srivastava S. K. , Awasthi Y. C. 1986 Dinitrophenyl glutathione efflux from human erythrocytes is primary active ATP-dependent transport Biochem J 238 443 - 449
Leake K. , Singhal J. , Nagaprashantha L. D. , Awasthi S. , Singhal S. S. 2012 RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer PLoS One 7 e34582 -
Lee S. , Wurtzel J. G. , Singhal S. S. , Awasthi S. , Goldfinger L. E. 2012 RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization Cancer Res 72 5165 - 5173    DOI : 10.1158/0008-5472.CAN-12-0468
Margutti P. , Matarrese P. , Conti F. , Colasanti T. , Delunardo F. , Capozzi A. , Garofalo T. , Profumo E. , Rigano R. , Siracusano A. , Alessandri C. , Salvati B. , Valesini G. , Malorni W. , Sorice M. , Ortona E. 2008 Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis Blood 111 4559 - 4570    DOI : 10.1182/blood-2007-05-092825
Matarrese P. , Colasanti T. , Ascione B. , Margutti P. , Franconi F. , Alessandri C. , Conti F. , Riccieri V. , Rosano G. , Ortona E. , Malorni W. 2011 Gender disparity in susceptibility to oxidative stress and apoptosis induced by autoantibodies specific to RLIP76 in vascular cells Antioxid Redox Signal 15 2825 - 2836    DOI : 10.1089/ars.2011.3942
Mollberg N. M. , Steinert G. , Aigner M. , Hamm A. , Lin F. J. , Elbers H. , Reissfelder C. , Weitz J. , Buchler M. W. , Koch M. 2012 Overexpression of RalBP1 in colorectal cancer is an independent predictor of poor survival and early tumor relapse Cancer Biol Ther 13 694 - 700    DOI : 10.4161/cbt.20087
Nakashima S. , Morinaka K. , Koyama S. , Ikeda M. , Kishida M. , Okawa K. , Iwamatsu A. , Kishida S. , Kikuchi A. 1999 Small G protein Ral and its downstream molecules regulate endocytosis of EGF and insulin receptors EMBO J 18 3629 - 3642    DOI : 10.1093/emboj/18.13.3629
Savai R. , Langheinrich A. C. , Schermuly R. T. , Pullamsetti S. S. , Dumitrascu R. , Traupe H. , Rau W. S. , Seeger W. , Grimminger F. , Banat G. A. 2009 Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer Neoplasia 11 48 - 56
Saxena M. , Singhal S. S. , Awasthi S. , Singh S. V. , Labelle E. F. , Zimniak P. , Awasthi Y. C. 1992 Dinitrophenyl S-glutathione ATPase purified from human muscle catalyzes ATP hydrolysis in the presence of leukotrienes Arch Biochem Biophys 298 231 - 237    DOI : 10.1016/0003-9861(92)90117-F
Sharma R. , Gupta S. , Singh S. V. , Medh R. D. , Ahmad H. , LaBelle E. F. , Awasthi Y. C. 1990 Purification and characterization of dinitrophenylglutathione ATPase of human erythrocytes and its expression in other tissues Biochem Biophys Res Commun 171 155 - 161    DOI : 10.1016/0006-291X(90)91370-8
Sharma R. , Singhal S. S. , Cheng J. , Yang Y. , Sharma A. , Zimniak P. , Awasthi S. , Awasthi Y. C. 2001 RLIP76 is the major ATP-dependent transporter of glutathione-conjugates and doxorubicin in human erythrocytes Arch Biochem Biophys 391 171 - 179    DOI : 10.1006/abbi.2001.2395
Sharma R. , Singhal S. S. , Wickramarachchi D. , Awasthi Y. C. , Awasthi S. 2004 RLIP76-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance Int J Cancer 112 934 - 942    DOI : 10.1002/ijc.20516
2007 Bv8 regulates myeloid-cell-dependent tumour angiogenesis Nature 450 825 - 831    DOI : 10.1038/nature06348
2006 Regression of melanoma in a murine model by RLIP76 depletion Cancer Res 66 2354 - 2360    DOI : 10.1158/0008-5472.CAN-05-3534
2009 Regression of prostate cancer xenografts by RLIP76 depletion Biochem Pharmacol 77 1074 - 1083    DOI : 10.1016/j.bcp.2008.11.013
1991 The anionic conjugates of bilirubin and bile acids stimulate ATP hydrolysis by S-(dinitrophenyl) glutathione ATPase of human erythrocyte FEBS Lett 281 255 - 257    DOI : 10.1016/0014-5793(91)80405-R
2007 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer Int J Oncol 30 717 - 725
2007 Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1) Cancer Res 67 4382 - 4389    DOI : 10.1158/0008-5472.CAN-06-4124
2009 RLIP76: a target for kidney cancer therapy Cancer Res 69 4244 - 4251    DOI : 10.1158/0008-5472.CAN-08-3521
2008 Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1 J Biol Chem 283 19714 - 19729    DOI : 10.1074/jbc.M708703200
2009 RLIP76: a novel glutathione-conjugate and multi-drug transporter Biochem Pharmacol 77 761 - 769    DOI : 10.1016/j.bcp.2008.10.006
2005 Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin Biochem Pharmacol 70 481 - 488    DOI : 10.1016/j.bcp.2005.05.005
2011 Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis Mol Cancer Ther 10 16 - 28
1998 ATP-dependent transport of glutathione conjugate of 7beta, 8alpha-dihydroxy-9alpha,10alpha-oxy-7,8,9,10-tetrahydrobenzo[a]pyrene in murine hepatic canalicular plasma membrane vesicles Biochem J 332 799 - 805
2005 RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer Cancer Res 65 991 - 998
2010 RLIP76: a versatile transporter and an emerging target for cancer therapy Biochem Pharmacol 79 1699 - 1705    DOI : 10.1016/j.bcp.2010.01.016
2008 Three-dimensional analysis of vascular development in the mouse embryo PLoS One 3 e2853 -
2010 Comparative structural and hemodynamic analysis of vascular trees Am J Physiol Heart Circ Physiol 298 H1249 - H1259